 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | MK-8558 / Merck (MSD)
Trial completion, Monotherapy: Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Na (clinicaltrials.gov) - May 15, 2020
P1, N=21, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed
- | MK-8558 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy: Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Na (clinicaltrials.gov) - Jan 13, 2020
P1, N=24, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Trial completion date: Mar 2020 --> Jul 2020 | Trial primary completion date: Mar 2020 --> Jul 2020
- | MK-8558 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy: Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Na (clinicaltrials.gov) - Jul 22, 2019
P1, N=24, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Mar 2020 --> Jul 2020 | Trial primary completion date: Mar 2020 --> Jul 2020 Trial completion date: Sep 2019 --> Dec 2019 | Trial primary completion date: Sep 2019 --> Dec 2019
- | MK-8558 / Merck (MSD)
Enrollment open, Monotherapy: Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Na (clinicaltrials.gov) - May 12, 2019
P1, N=24, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Sep 2019 --> Dec 2019 | Trial primary completion date: Sep 2019 --> Dec 2019 Not yet recruiting --> Recruiting
- | MK-8558 / Merck (MSD)
Trial completion date, Trial primary completion date, Monotherapy: Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Na (clinicaltrials.gov) - Mar 30, 2019
P1, N=24, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Trial completion date: Jan 2020 --> Sep 2019 | Trial primary completion date: Dec 2019 --> Sep 2019
- | MK-8558 / Merck (MSD)
New P1 trial, Monotherapy: Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Na (clinicaltrials.gov) - Mar 1, 2019
P1, N=24, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.